Hunterdon Pharmaceuticals Inc said formed joint venture & lt ; Chesapeake Biological Laboratories > & lt ; E.B .
Michaels Research Associates > develop C31G , substance may useful treatment prevention plaque .
The substance , tested pre-clinical trial University Pennsylvania , also us anti-fungal anti-bacterial agent , company said .
It said Chesapeake Biological , private company , owns 55 pct venture , E.B .
Michaels 10 pct , hold remaining interest , patent C31G .
Reuter & # 3 ; 